We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
-13.68%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$179M
AUM Growth
-$34.5M
Cap. Flow
+$6.04M
Cap. Flow %
3.37%
Top 10 Hldgs %
60.25%
Holding
55
New
14
Increased
12
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$4.1M
2
DTIL icon
Precision BioSciences
DTIL
+$4.01M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$2.67M
4
UTHR icon
United Therapeutics
UTHR
+$2.64M
5
RZLT icon
Rezolute
RZLT
+$2.14M

Top Sells

Rank Stock Value
1
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$5.52M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$3.96M
3
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$2.47M
4
GHRS icon
GH Research
GHRS
+$2.29M
5
LONA
LeonaBio Inc
LONA
+$1.89M

Sector Composition

Rank Sector Weight
1 Healthcare 88.88%
2 Financials 7.74%
3 Miscellaneous 3.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
26
PMV Pharmaceuticals
PMVP
$78M
$2.17M 1.21%
152,500
+17,000
+13% +$247K
RZLT icon
27
Rezolute
RZLT
$380M
$2.08M 1.16%
+645,136
New +$2.14M
IOVA icon
28
Iovance Biotherapeutics
IOVA
$4.54B
$1.7M 0.95%
154,356
+35,500
+30% +$465K
PYXS icon
29
Pyxis Oncology
PYXS
$284M
$1.53M 0.86%
645,149
+445,149
+223% +$1.19M
VTYX
30
DELISTED
Ventyx Biosciences
VTYX
$1.49M 0.83%
122,000
+51,123
+72% +$764K
ENTA icon
31
Enanta Pharmaceuticals
ENTA
$365M
$1.3M 0.72%
27,500
+25,200
+1,096% +$1.37M
ITOS
32
DELISTED
iTeos Therapeutics
ITOS
$1.28M 0.71%
+62,000
New +$1.47M
ACAD icon
33
Acadia Pharmaceuticals
ACAD
$4.73B
$1.01M 0.56%
+71,500
New +$1.33M
FULC icon
34
Fulcrum Therapeutics
FULC
$288M
$980K 0.55%
200,000
– –
GOSS icon
35
Gossamer Bio
GOSS
$73M
$268K 0.15%
+400
New +$248K
VSTM icon
36
Verastem
VSTM
$684M
$232K 0.13%
16,667
-66,412
-80% -$1.06M
SWTX
37
DELISTED
SpringWorks Therapeutics
SWTX
$123K 0.07%
+5,000
New +$183K
TRVI icon
38
Trevi Therapeutics
TRVI
$2.17B
$98K 0.05%
+35,000
New +$86K
OCUL icon
39
Ocular Therapeutix
OCUL
$2.23B
$53K 0.03%
+13,171
New +$49.8K
NUVB.WS
40
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$25K 0.01%
+90,832
New +$58.4K
ACIU icon
41
CALL
AC Immune
ACIU
$266M
– –
-100,000
Closed -$400K
LONA
42
CALL
LeonaBio Inc
LONA
$65.5M
– –
-10,000
Closed -$1.35M
LONA
43
LeonaBio Inc
LONA
$65.5M
– –
-14,003
Closed -$1.89M
AVDL
44
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-580,000
Closed -$3.96M
NUVB icon
45
Nuvation Bio
NUVB
$2.13B
– –
-90,832
Closed -$69K
PMVP icon
46
CALL
PMV Pharmaceuticals
PMVP
$78M
– –
-100,000
Closed -$2.08M
SEEL
47
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
-77
Closed -$248K
IMGN
48
DELISTED
Immunogen Inc
IMGN
– –
-55,000
Closed -$262K
HARP
49
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-49,750
Closed -$2.47M
MTEM
50
DELISTED
Molecular Templates, Inc.
MTEM
– –
-20,475
Closed -$1.06M
1
2
3

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Acuta Capital Partners held 55 positions worth $179M, down 16% from $214M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners deployed $6.04M of net new capital in Q2 2022, opening 14 new positions and adding to 12 existing holdings. Its largest new stake was Arcus Biosciences: 167,500 shares worth $4.24M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was GH Research, an estimated $2.29M trimmed.

  • Acuta Capital Partners's largest Q2 2022 buy was Arcus Biosciences: 167,500 shares worth $4.24M.
  • Acuta Capital Partners added most to Mirati Therapeutics, Inc. Common Stock in Q2 2022, an estimated $2.67M increase.
  • Acuta Capital Partners's biggest Q2 2022 reduction was GH Research, cutting an estimated $2.29M.
  • Acuta Capital Partners fully exited Jounce Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $5.52M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $179M portfolio in Q2 2022.
  • Acuta Capital Partners opened 14 new positions and closed 12 in Q2 2022.
  • Acuta Capital Partners's portfolio value fell 16% quarter-over-quarter to $179M.

Based on Acuta Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.